methylprednisolone and bortezomib

methylprednisolone has been researched along with bortezomib in 21 studies

Research

Studies (21)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (38.10)	29.6817
2010's	11 (52.38)	24.3611
2020's	2 (9.52)	2.80

Authors

Authors	Studies
Lombardo, F; Obach, RS; Waters, NJ	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Ferrant, A; Jacquemain, A; Knoops, L; Tennstedt, D; Theate, I; Van den Neste, E	1
Chim, CS; Ooi, GC	1
De Raeve, H; Lambert, J; Rombouts, S; Schroyens, W; Van de Velde, A; Van de Voorde, K; Van Regenmortel, N	1
Jagannath, S	1
Abonour, R; Juliar, BE; Smith, GG; Suvannasankha, A	1
Astori, C; Castagnola, C; Corso, A; Dore, R; Lazzarino, M; Mangiacavalli, S; Varettoni, M; Zappasodi, P	1
Chen, SL; Hu, Y; Li, X; Zhang, JJ; Zhong, YP	1
An, N; Chen, SL; Hu, Y; Li, X; Zhang, JJ; Zhong, YP	1
Suzuki, K	1
Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K	1
Butani, L; Gallay, B; Nguyen, S	1
Alkemper, B; Gaede, B; Knauf, W; Reschke, D; Schlag, R; Schmits, R; Schütz, S; Schwarzer, A; Tapprich, C	1
Gazdic, T; Kautzner, J; Kment, M; Kubanek, M; Malek, I; Pagacova, L; Svobodova, E; Viklicky, O	1
Hou, J; Hu, W; Huang, L; Huang, X; Liu, Z; Zhang, H; Zhou, M	1
Thakkar, UG; Trivedi, HL; Vanikar, AV	1
Bahlis, NJ; Duggan, P; Jimenez-Zepeda, VH; Lee, H; McCulloch, S; Neri, P; Tay, J	1
Chen, M; Huang, Y; Jia, L; Li, Y; Liu, H; Lv, L; Wang, J; Yang, C; Yao, M; Zhang, H; Zhang, J	1

Reviews

2 review(s) available for methylprednisolone and bortezomib

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. Clinical and experimental nephrology, 2012, Volume: 16, Issue:5 Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide	2012

Article

Year

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.

Drug discovery today, 2016, Volume: 21, Issue:4

Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.

Clinical and experimental nephrology, 2012, Volume: 16, Issue:5

Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide

2012

Trials

3 trial(s) available for methylprednisolone and bortezomib

Article	Year
Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clinical lymphoma & myeloma, 2006, Volume: 7, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Rate	2006
[Bortezomib combined with other drugs for treating 60 cases of multiple myeloma]. Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome	2009
Bortezomib-containing regimens are effective in multiple myeloma--results of a non-interventional phase IV study. Oncology research and treatment, 2015, Volume: 38, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prospective Studies	2015

Other Studies

16 other study(ies) available for methylprednisolone and bortezomib

Article	Year
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Bortezomib-induced Sweet syndrome. British journal of haematology, 2005, Volume: 131, Issue:2 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Glucocorticoids; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Sweet Syndrome	2005
Bulbar palsy in multiple myeloma. Haematologica, 2005, Volume: 90, Issue:12 Suppl Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Bulbar Palsy, Progressive; Combined Modality Therapy; Cranial Fossa, Posterior; Cranial Nerve Diseases; Cyclosporine; Dexamethasone; Disease Progression; Doxorubicin; Fatal Outcome; Female; Graft vs Host Disease; Humans; Immunocompromised Host; Immunoglobulin Light Chains; Immunosuppressive Agents; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pneumonia, Aspiration; Pyrazines; Reflex, Abnormal; Transplantation, Homologous; Vincristine	2005
Bortezomib-induced Sweet's syndrome. Haematologica, 2005, Volume: 90, Issue:12 Suppl Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Erectile Dysfunction; Humans; Immunosuppressive Agents; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Prednisolone; Protease Inhibitors; Pyrazines; Recurrence; Sleep Initiation and Maintenance Disorders; Sweet Syndrome; Testicular Diseases	2005
Bortezomib dosing in relapsed multiple myeloma. Clinical lymphoma & myeloma, 2006, Volume: 7, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Rate	2006
Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22 Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cryptogenic Organizing Pneumonia; Glucocorticoids; Humans; Male; Methylprednisolone; Multiple Myeloma; Pyrazines; Tomography, X-Ray Computed	2007
[Effects of bortezomib combined with methylprednisolone in treatment of 33 cases of relapsed or refractory multiple myeloma]. Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Retrospective Studies; Treatment Outcome	2011
Myeloma presenting during pregnancy. Hematological oncology, 2014, Volume: 32, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous	2014
Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen. Pediatric transplantation, 2014, Volume: 18, Issue:5 Topics: Adolescent; Antibodies; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Glomerular Filtration Rate; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunosuppression Therapy; Immunosuppressive Agents; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Male; Methylprednisolone; Plasmapheresis; Pyrazines; Retrospective Studies; Rituximab; Steroids; Tissue Donors; Treatment Outcome; Young Adult	2014
Bortezomib-containing regimen for primary treatment of early antibody-mediated cardiac allograft rejection: a case report. Progress in transplantation (Aliso Viejo, Calif.), 2015, Volume: 25, Issue:2 Topics: Adult; Allografts; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Graft Rejection; Heart Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Methylprednisolone; Prospective Studies; Pyrazines; Rituximab; Treatment Outcome	2015
The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. Lupus, 2017, Volume: 26, Issue:9 Topics: Administration, Intravenous; Adult; Antineoplastic Agents; Autoantibodies; Bortezomib; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Kidney; Lupus Nephritis; Male; Methylprednisolone; Prednisone; Proteinuria; Remission Induction	2017
Six years' experience of tolerance induction in renal transplantation using stem cell therapy. Clinical immunology (Orlando, Fla.), 2018, Volume: 187 Topics: Adipose Tissue; Adult; Antibodies; Antilymphocyte Serum; Antineoplastic Agents; Bortezomib; Female; Glucocorticoids; Graft Rejection; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immune Tolerance; Immunologic Factors; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Lymphocyte Culture Test, Mixed; Male; Mesenchymal Stem Cell Transplantation; Methylprednisolone; Rituximab; Transplantation Conditioning	2018
The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience. European journal of haematology, 2021, Volume: 106, Issue:3 Topics: Aged; Alberta; Antibodies, Monoclonal; Basement Membrane; Bortezomib; COVID-19; COVID-19 Testing; Cyclophosphamide; Dexamethasone; Disease Management; Disease Susceptibility; Drug Therapy, Combination; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Kaplan-Meier Estimate; Lenalidomide; Male; Methylprednisolone; Middle Aged; Neoplasm, Residual; Pandemics; Paraproteinemias; Precision Medicine; Retrospective Studies; SARS-CoV-2; Telemedicine	2021
Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia. Medicine, 2022, Jan-28, Volume: 101, Issue:4 Topics: Adult; Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Methylprednisolone; Middle Aged; Rituximab; Treatment Outcome	2022